Identifying status of male fertility by determining sperm capacitation and companion collection kit
The method and kit for diluting and storing sperm samples at 4°C to 25°C extend the time for assessing male fertility, allowing at-home collection and accurate Cap-Score analysis, enhancing convenience and accessibility.
Patent Information
- Application Number
- JP2024133326
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-08-09
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-19
AI Technical Summary
Existing methods for assessing male fertility through sperm capacitation, such as the Cap-Score assay, require fresh sperm samples prepared within 2 hours and transported to a laboratory, limiting convenience and accessibility for patients.
A method and kit for diluting sperm samples with a semen diluent and maintaining them at a temperature range of 4°C to 25°C for extended periods, allowing at-home collection and overnight transport without compromising assay accuracy.
Enables convenient at-home sperm sample collection and extended storage, maintaining sperm viability and capacitation potential, ensuring accurate Cap-Score results upon laboratory analysis.
Smart Images

Figure 2024161437000001_ABST
Abstract
Description
[Technical field]
[0001] Cross-reference to related art This application claims priority to U.S. Provisional Application No. 62 / 884,785, filed August 9, 2019, and U.S. Provisional Application No. 62 / 755,087, filed November 2, 2018, which are incorporated by reference in their entireties.
[0002] The present invention relates generally to the field of male fertility, and more particularly to the determination of sperm capacitation from sperm samples stored for more than two hours in a medium containing an extender solution maintained at about 4° C. to about 25° C., followed by the determination of ganglioside, G M1 To determine male fertility based on the distribution pattern of TM A companion recovery kit for use in the assay. [Background technology]
[0003] In the United States, 10% of couples have medical findings related to infertility, and approximately 40% to 50% of infertility cases are male-attributable. On a global scale, this translates to over 73 million infertile couples. A typical male reproductive health test evaluates sperm count, appearance, and motility. Unfortunately, over half of infertile men have sperm that meet the normal parameters of these descriptive criteria and are deemed to have "idiopathic infertility" after repeated failures of both natural conception and assisted reproductive techniques such as intrauterine insemination (IUI). Since each failed cycle takes a great physical, emotional, and financial toll on couples and costs the U.S. health care system over $5 billion annually, there is a great need for practical testing of sperm function (Non-Patent Document 1). Such testing allows clinicians to guide patients to assisted reproductive techniques that will give them the best chance of producing a pregnancy (Non-Patent Document 2).
[0004] When sperm enter the female reproductive tract, they cannot immediately fertilize an egg. Rather, they must undergo a functional maturation process known as "capacitation." This process involves specific changes in the cell membrane, namely the uptake of ganglioside G in response to exposure to capacitation cues. M1 The ability to respond to a particular stimulus depends on the change in the distribution pattern of the
[0005] Cap-Score TM The assay detects specific G M1 It is used to assess male fertility by measuring differences in distribution patterns. TM For the assay, sperm samples were typically freshly prepared, kept warm at body temperature, and transported to the testing laboratory within approximately 30 minutes. TM When performing the assay, sperm samples were not stored for longer than 2 hours (Non-Patent Document 2). Summary of the Invention
[0006] The present invention relates to a method for diluting a sperm sample and a method for determining the Cap-Score. TM The present invention provides a method for extending the storage time of a sperm sample prior to preparing the sperm sample for assay. More specifically, the present invention provides a method for improving the resistance of sperm cells to capacitation when stored under specified conditions for at least 2 hours or more, allowing a patient (or physician) to collect a sperm sample and assess the collected sperm sample using a Cap-Score®. TM The convenience of at-home collection of sperm samples allows for the Cap-Score assay to be performed without compromising accuracy and efficiency. TM Greatly improves assay utility.
[0007] In an embodiment of the present invention, the present disclosure provides a method for determining male fertility status.
[0008] In one embodiment, a method for determining the fertility status of a human male comprises the steps of: a) obtaining a sperm sample from a human male; b) introducing a volume of a semen diluent solution into said sperm sample in a dilution volume ratio to obtain a diluted sperm sample; c) maintaining said diluted sperm sample at a temperature range of about 4° C. to about 25° C. for an extended period of time of more than 2 hours; and d) determining the percentage of sperm that can undergo capacitation (Cap-Score). TM To determine the Cap-Score for the diluted sperm sample of step (c), TM and e) performing the assay to determine the fertility status of the human male. TM Cap-Score obtained from the assay TM is the Cap-Score obtained from a fresh sample obtained from the same individual and treated in the same way. TM There is no significant difference.
[0009] In one embodiment, a method for determining a human male's fertility status comprises maintaining a temperature of a diluted sperm sample in the range of about 4° C. to about 25° C. for more than 2 hours. In some embodiments, a method for determining a human male's fertility status comprises maintaining a temperature of a diluted sperm sample in the range of about 4° C. to about 10° C. for more than 2 hours.
[0010] In some embodiments, the long period for storage of the sperm sample is from about 2 hours to about 24 hours. In some embodiments, the long period for transport of the sperm sample is from about 12 hours to about 48 hours. In some embodiments, the long period for transport of the sperm sample is at least 12 hours. In some embodiments, the long period for transport of the sperm sample is at least 18 hours.
[0011] In some embodiments, the semen diluent comprises a buffer system. Any buffer system known in the art is useful in the present invention. In some embodiments, the semen diluent comprises a buffer selected from the group consisting of bicarbonate buffer, citrate buffer, hydroxymethylaminomethane (TRIS) buffer, TRIS / citrate buffer, TRIS / citrate buffer, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer, HEPES / TRIS buffer, N'-tris(hydroxymethyl)methyl-2-aminoethane (TES) and hydroxymethylaminomethane (TRIS) buffer (TES / TRIS buffer), and combinations thereof. In some embodiments, the buffer comprises a TES / TRIS buffer (or "TEST" buffer).
[0012] In some embodiments, the semen diluent comprises at least one protein. In some embodiments, the protein is selected from the group consisting of albumin, horse serum, bovine serum, soy protein, fetal umbilical cord serum ultrafiltrate, plasmanate, egg yolk, skim milk, lipoproteins, fatty acid binding proteins, and combinations thereof. In some embodiments, the semen diluent solution comprises a protein selected from the group consisting of egg yolk, milk proteins, and combinations thereof. In one embodiment, the semen diluent solution comprises egg yolk.
[0013] In some embodiments, the semen diluent further comprises an antibiotic. In some embodiments, the antibiotic is selected from the group consisting of gentamicin, penicillin, streptomycin, amphotericin, and combinations thereof. In embodiments, the antibiotic is gentamicin.
[0014] In some embodiments, the method further comprises the steps of: TMPrior to performing the assay, one or more additional steps may be performed, in some embodiments, selected from centrifuging the diluted semen sample to separate the seminal plasma from the sperm cells and recover a sperm cell pellet, resuspending the sperm cell pellet in medium containing one or more capacitation stimuli, such as mHTF (Cap) and optionally in medium not containing the capacitation stimuli, such as mHTF (non-Cap), and incubating the resulting cell suspension in Cap medium and optionally in non-Cap medium at 37° C. for 3 hours.
[0015] In some embodiments, the dilution volume ratio of the sperm sample to the semen diluent solution is about 10:1 to about 1:10. In some embodiments, the dilution volume ratio of the sperm sample to the semen diluent solution is about 1:10. In some embodiments, the dilution volume ratio of the sperm sample to the semen diluent solution is about 10:1. In some embodiments, the dilution volume ratio of the sperm sample to the semen diluent solution is about 1:1.
[0016] In some embodiments, the sperm sample is stored in a plastic tube with a conical bottom and a sealed cap, hi some embodiments, the plastic tube is selected from the group consisting of polypropylene, polystyrene, polyethylene terephthalate (PET), low density polyethylene (LDPE), polyallomer (PA), and polycarbonate (PC).
[0017] In some embodiments, the method further comprises using a sperm sample collection kit comprising one or more of a sperm storage container, a transfer pipette, an insulating pouch, a cold pack, an insulated container, and a semen diluent solution.
[0018] In an embodiment, the present disclosure provides a method for determining the fertility status of a human male individual, comprising the steps of: a) obtaining a sperm sample from a human male; b) introducing a volume of a semen diluent solution to the sperm sample in a dilution volume ratio to obtain a diluted sperm sample; c) cooling the diluted sperm sample of step b) in an insulated container to a temperature ranging from about 4° C. to about 10° C. to obtain a cooled diluted sperm sample; d) maintaining the cooled diluted sperm sample at a temperature ranging from about 4° C. to about 25° C. for an extended period of time, the temperature being maintained by placing the diluted sperm sample in an insulated pouch with a cold pack cooled to a predetermined temperature; and e) performing a Cap-Score on the diluted sperm sample of step (d). TM Assay (G due to capacitation) M1 and determining a distribution of patterns of the fertility patterns of the human male to determine the fertility status of the human male.
[0019] In some embodiments, the cooling step (c) is carried out for about 1 hour. In some embodiments, the extended period in step (d) is at least 18 hours. In some embodiments, the cold pack is cooled to 4° C. In some embodiments, the cold pack is cooled to −20° C. In some embodiments, the method further comprises using a companion sperm sample collection kit comprising one or more of a sperm storage container, a transfer pipette, an insulating pouch, a cold pack, an insulated container, and a semen diluent solution.
[0020] In embodiments, the present invention includes sperm storage containers, transfer pipettes, insulating pouches, cold packs, thermally insulated containers, semen diluent solutions, agents for stimulating capacitation, capacitation media, non-capacitation media, fixation reagents, and G M1 A kit for determining male fertility status is provided which includes one or more of the reagents for determining the pattern distribution. [Brief description of the drawings]
[0021] [Figure 1]Figure 1 shows a flow chart illustrating semen sample preparation and timeline.
[0022] [Diagram 2] FIG. 2, including FIGS. 2A-2E, illustrates the transport of diluted unprocessed human ejaculate using an at-home collection kit that includes a cold pack cooled to 4° C.
[0023] [Diagram 3] FIG. 3 shows the temperature profile measured over a 24 hour period of a cold pack cooled to 4° C. in a sealed insulated Styrofoam container.
[0024] [Figure 4] FIG. 4, comprising FIGS. 4A-4D, shows monitoring of the temperature profile of a semen sample maintained in a 4° C. refrigerator.
[0025] [Diagram 5] FIG. 5 shows the temperature profile of samples kept in a refrigerator at 4° C. over a 24 hour period.
[0026] [Figure 6] FIG. 6 shows the results of the Cap-Score™ test on samples stored in sealed insulated styrofoam containers with cold packs cooled to 4° C.
[0027] [Figure 7] FIG. 7 shows the results of the Cap-Score™ test for samples kept in a refrigerator at 4° C.
[0028] [Figure 8] FIG. 8, comprising FIGS. 8A-8E, illustrates the transport of diluted raw human ejaculate using an at-home collection kit containing cold packs cooled to −20° C.
[0029] [Figure 9]FIG. 9 shows the temperature profile measured over a 24 hour period produced by a cold pack cooled to −20° C. in a sealed insulated Styrofoam container. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0030] This disclosure relates to a specific G M1 It is based on the finding that distribution patterns may provide information about male fertility status. M1 Determining the pattern is described, for example, in U.S. Patent Nos. 7,160,676, 7,670,763, and 8,367,313, and U.S. Publication No. 20170248584, the disclosures of which are incorporated herein by reference. TM The assay detects specific G M1 The present disclosure provides a method and companion collection / transport kit for determining male fertility status. The companion kit includes a semen diluent solution for maintaining sperm cell viability during extended sperm storage and transport for periods of more than 2 hours.
[0031] In the present disclosure, semen can be collected in a private setting, such as a patient's home, and the resulting Cap-Score TM The unexpected finding is that the composition can be prepared and stored for overnight transport without significant adverse effects or significant changes to the composition. definition
[0032] Unless otherwise defined in the preceding sections and throughout the remainder of this specification, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patents and publications mentioned herein are incorporated by reference in their entirety.
[0033] The term "capacitation" (Cap) conditions as used herein generally refers to conditions in which sperm cells are incubated with one or more stimuli for capacitation. Specifically, this requires the presence of bicarbonate and / or calcium ions in the medium, and the presence of a sterol acceptor, such as serum albumin or cyclodextrin. Sperm that successfully respond to capacitation conditions acquire the ability to undergo acrosome exocytosis and a hyperactivation pattern of motility.
[0034] As used herein, the term "non-capacitation" (non-Cap) conditions refers to conditions in which sperm cells are not incubated with one or more stimuli for capacitation. Sperm that are not exposed to capacitation conditions, or that are exposed but do not respond to capacitation conditions, do not undergo acrosomal exocytosis induced by the zona pellucida, solubilized proteins from the zona pellucida, or physiological ligands such as progesterone. Furthermore, such sperm do not exhibit hyperactivated motility.
[0035] As used herein, the term "Cap-Score" TM The term "assay" generally refers to a method for determining the fertility status of a human male individual, comprising the following steps (1) to (3): M1 (2) staining fixed and capacitated sperm samples and, optionally, fixed and uncapacitated sperm samples from the same individual for selected G M1 (3) determining the frequency of the selected G patterns associated with sperm that respond to the capacitation conditions; M1 The frequency of the pattern was compared with the sperm G M1 and comparing the total frequency of the patterns to a reference value in a population of known fertility. This test provides an analysis of the sperm at a molecular level and determines the percentage of sperm that are capable of capacitation (Cap-Score TM ).
[0036] In some embodiments, methods for determining male fertility status are described. In some embodiments, the methods include obtaining a sperm sample from an individual. In some embodiments, the sperm sample is obtained using a home collection kit, as described in more detail herein. In some embodiments, the sperm sample is collected by the individual in a home environment. In some embodiments, the sperm sample is collected at a doctor's office, laboratory, or clinic.
[0037] In some embodiments, the semen sample is Cap-Score TM Prior to performing the assay, the sample is stored in a container with a reclosable lid. In some embodiments, the container can be plastic, glass, or other durable material. In some embodiments, the container is plastic. In some embodiments, the container comprises a plastic selected from the group consisting of polypropylene, polystyrene, polyethylene terephthalate (PET), low density polyethylene (LDPE), polyallomer (PA), and polycarbonate (PC).
[0038] In some embodiments, the sperm sample is mixed with a semen diluent.
[0039] In some embodiments, the use of a semen diluent is employed to extend the viability of the sperm sample. In some embodiments, the semen diluent is any commercially available or later developed semen diluent solution. The semen diluent represents an osmotically balanced salt solution and may include one or more of an energy source (e.g., sugars such as glucose, fructose, dextrose, sucrose, sorbitol, pyruvate, etc.), lipids (e.g., soy lecithin, egg yolk lipids, milk lipids), a protein source (e.g., casein, albumin, seminal plasma), antibiotics (e.g., gentamicin, penicillin, streptomycin, amphotericin), a buffer system, and / or electrolytes (e.g., balanced and isotonic electrolyte solutions, TRIS, TES, TES / TRIS (TEST), citric acid, sodium citrate, HEPES). In some embodiments, the semen diluent includes egg yolk, glucose, and citrate.
[0040] In some embodiments, the semen diluent comprises one or more proteins or lipids for use as cryoshock protectants. In some embodiments, the semen diluent comprises a protein selected from the group consisting of albumin, horse serum, bovine serum, soy protein, soy lecithin, fetal umbilical cord serum ultrafiltrate, plasmanate, egg yolk, egg yolk lecithin, skim milk, casein, lipoproteins, fatty acid binding proteins, and combinations thereof. In some embodiments, the semen diluent comprises a protein selected from the group consisting of egg yolk, soy protein, milk, and combinations thereof. In some embodiments, the protein comprises egg yolk. In some embodiments, the protein comprises chicken egg yolk. The major component of egg yolk plasma is low density lipoprotein (LDL). Egg yolk LDL has a liquid lipid core surrounded by phospholipids. In some embodiments, the protein comprises LDL.
[0041] In some embodiments, the protein comprises whole egg yolk, hi some embodiments, the protein comprises a fraction of whole egg yolk, e.g., clarified egg yolk prepared by centrifugation of whole egg yolk, or low density protein prepared by extraction of the LDL fraction from egg yolk plasma.
[0042] In some embodiments, the semen diluent comprises a phospholipid derived from an animal source, such as LDL phospholipid (egg yolk lecithin). In some embodiments, the semen diluent comprises a phospholipid derived from a non-animal source, such as soy lecithin.
[0043] In some embodiments, the semen diluent can be biologically buffered to exhibit a pH that maintains cell viability. In some embodiments, the semen diluent includes a buffer to maintain a pH of about 6.9 to about 7.5 in the semen diluent. In some embodiments, the pH is maintained at about 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, or 7.5. Commonly used biological buffers are available under names such as TRIS, HEPES, and TES. The amount of biological buffer contained in the diluent depends on the strength of the biological buffer and the desired buffering capacity of the diluent, for example, commonly used buffer concentrations include about 10 mM bicarbonate, 20-25 mM HEPES, or about 20-25 mM TRIS-HCl.
[0044] In some embodiments, the semen diluent is selected from the group consisting of bicarbonate buffer, citrate buffer, sodium citrate buffer, hydroxymethylaminomethane (TRIS) buffer, TRIS / citrate buffer, TRIS / citrate buffer, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer, HEPES / TRIS buffer, N'-tris(hydroxymethyl)methyl-2-aminoethane (TES) and hydroxymethylaminomethane (TRIS) buffer (TES / TRIS buffer), tris(hydroxymethyl)methylamino]propanesulfonic acid (TAP) buffer, and the like. S) buffer, 2-(Bis(2-hydroxyethyl)amino)acetic acid (Bicine) buffer, 3-[N-Tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonic acid (Tricine) buffer, 3-[N-Tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonic acid (TAPSO) buffer, 3-(N-Morpholino)propanesulfonic acid (MOPS) buffer, piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES) buffer, 2-(N-Morpholino)ethanesulfonic acid (MES) buffer, and combinations thereof.
[0045] In some embodiments, the semen diluent is an egg yolk-based diluent. In some embodiments, the egg yolk-based diluent can comprise 16.0% to 24.0% by volume of egg yolk and 45.0% to 70.0% by volume of a buffer solution. In some embodiments, the egg yolk-based diluent comprises whole chicken egg yolk. In some embodiments, the egg yolk-based diluent can comprise 16.0%, 20.0%, or 24.0% by volume of egg yolk.
[0046] In some embodiments, the semen diluent comprises egg yolk and a citrate buffer. In some embodiments, the egg yolk based diluent comprises egg yolk and a TRIS buffer. In some embodiments, the egg yolk based diluent comprises egg yolk and a TRIS / citrate buffer. In some embodiments, the egg yolk based diluent comprises egg yolk and a TRIS / citrate buffer. In some embodiments, the semen diluent comprises whole chicken egg yolk and a citrate buffer. In some embodiments, the egg yolk based diluent comprises whole chicken egg yolk and a TRIS buffer. In some embodiments, the egg yolk based diluent comprises whole chicken egg yolk and a TRIS / citrate ...
[0047] In some embodiments, the semen diluent exhibits an osmolality of about 250 mOsM to about 350 mOsM. In some embodiments, the semen diluent exhibits an osmolality of about 290 mOsM to about 320 mOsM. In some embodiments, the semen diluent comprises at least about 90% water by weight.
[0048] In some embodiments, the semen diluent can include an energy source such as carbohydrate to provide energy to the sperm cells. In some embodiments, the carbohydrate is a monosaccharide. In some embodiments, the carbohydrate is selected from the group consisting of sorbitol, fructose, sucrose, dextrose, glucose, and lactose. In some embodiments, the carbohydrate can be used alone or in combination with one or more other energy sources. In an embodiment of the invention, the carbohydrate is present in an amount sufficient to provide energy to the cells. In one embodiment, the amount of glucose as a carbohydrate source is about 0.09 g / L to about 1.8 g / L. In some embodiments, the amount of glucose as a carbohydrate source is about 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, or 3.0 g / L.
[0049] In some embodiments, the semen diluent comprises an antibiotic, hi some embodiments, the antibiotic is a compound selected from the group consisting of penicillins, tetracyclines, cephalosporins, lincomycins, macrolides, glycopeptides, aminoglycosides, carbapenems, and combinations thereof. In some embodiments, the antibiotic is selected from the group consisting of gentamicin, tobramycin, amikacin, penicillin, streptomycin, amoxicillin, doxycycline, minocycline, tetracycline, eravacycline, cephalexin, clindamycin, lincomycin, clarithromycin, erythromycin, metronidazole, azithromycin, levofloxacin, moxifloxacin, cefuroxime, ceftriaxone, cefdinir, dalbavancin, oritavancin, telavancin, vancomycin, ertapenem, doripenem, meropenem, imipenem / cilastatin, bacitracin, neomycin, polymyxin B, amphotericin, and combinations thereof. In some embodiments, the antibiotic is gentamicin.
[0050] In some embodiments, the semen diluent is selected for its ability to maintain viability and motility of the initial sperm sample. In some embodiments, the viability of the sperm sample is at least 40% of the initial viability, and the motility corresponds to a level of at least 40% of the initial motility. In some embodiments, each of the viability and motility levels is at least about 70% of the initial value. In some embodiments, the components of the semen diluent composition included in the home collection kit of the present invention can be selected to help maintain the viability and motility of the sperm cells.
[0051] Semen diluents that may be useful in the present invention include: (1) CYB medium (Weidel et al., J. Androl. 8: 41-47 (1987)) and (2) Refrigerated Medium-TYB with gentamicin (Irvine Scientific, Santa Ana, Calif.; catalogue #90129).
[0052] In some embodiments, the semen diluent may include components derived from animal sources and / or the semen diluent composition may include components derived from non-animal sources. In some embodiments, the semen diluent may be characterized as being substantially free of components derived from animal sources. "Substantially free" should be understood to mean that the diluent contains less than about 0.1% by weight of components derived from animal sources. It should be understood that the characterization of the semen diluent as containing or not containing components derived from animal sources is not intended to reflect the semen or ejaculate that is added to the semen diluent composition.
[0053] In some embodiments, the semen diluent can be free of any components derived from animal sources. In some embodiments, the semen diluent composition can include one or more components derived from animals, and these components can be present in the semen diluent composition in an amount greater than 0.1% by weight based on the weight of the semen diluent composition.
[0054] In some embodiments, the sperm sample is introduced into the semen diluent solution at a dilution volume ratio of sperm sample to semen diluent solution of about 10:1 to about 1:10. In some embodiments, the dilution volume ratio of sperm sample to semen diluent solution is about 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10. In some embodiments, the dilution volume ratio of sperm sample to semen diluent solution is about 3:1, 2:1, or 1:1. In some embodiments, the dilution volume ratio of sperm sample to semen diluent solution is about 1:10. In some embodiments, the dilution volume ratio of sperm sample to semen diluent solution is about 1:10. In some embodiments, the dilution volume ratio of sperm sample to semen diluent solution is about 1:1.
[0055] In some embodiments, the sample is maintained at a temperature range selected from the group consisting of about 1°C to about 25°C, about 1°C to about 24°C, about 1°C to about 23°C, about 1°C to about 22°C, about 1°C to about 21°C, about 1°C to about 20°C, about 1°C to about 19°C, about 1°C to about 18°C, about 1°C to about 17°C, about 1°C to about 16°C, about 1°C to about 15°C, about 1°C to about 14°C, about 1°C to about 13°C, about 1°C to about 12°C, about 1°C to about 11°C, about 1°C to about 10°C, about 1°C to about 9°C, about 1°C to about 8°C, about 1°C to about 7°C, about 1°C to about 6°C, about 1°C to about 5°C, about 1°C to about 4°C, about 1°C to about 3°C, and about 1°C to about 2°C.
[0056] In some embodiments, the sample is maintained at a temperature range selected from the group consisting of about 2°C to about 25°C, about 2°C to about 24°C, about 2°C to about 23°C, about 2°C to about 22°C, about 2°C to about 21°C, about 2°C to about 20°C, about 2°C to about 19°C, about 2°C to about 18°C, about 2°C to about 17°C, about 2°C to about 16°C, about 2°C to about 15°C, about 2°C to about 14°C, about 2°C to about 13°C, about 2°C to about 12°C, about 2°C to about 11°C, about 2°C to about 10°C, about 2°C to about 9°C, about 2°C to about 8°C, about 2°C to about 7°C, about 2°C to about 6°C, about 2°C to about 5°C, about 2°C to about 4°C, and about 2°C to about 3°C.
[0057] In some embodiments, the sample is maintained at a temperature range selected from the group consisting of about 3°C to about 25°C, about 3°C to about 24°C, about 3°C to about 23°C, about 3°C to about 22°C, about 3°C to about 21°C, about 3°C to about 20°C, about 3°C to about 19°C, about 3°C to about 18°C, about 3°C to about 17°C, about 3°C to about 16°C, about 3°C to about 15°C, about 3°C to about 14°C, about 3°C to about 13°C, about 3°C to about 12°C, about 3°C to about 11°C, about 3°C to about 10°C, about 3°C to about 9°C, about 3°C to about 8°C, about 3°C to about 7°C, about 3°C to about 6°C, about 3°C to about 5°C, and about 3°C to about 4°C.
[0058] In some embodiments, the sample is maintained at a temperature range selected from the group consisting of about 4°C to about 25°C, about 4°C to about 24°C, about 4°C to about 23°C, about 4°C to about 22°C, about 4°C to about 21°C, about 4°C to about 20°C, about 4°C to about 19°C, about 4°C to about 18°C, about 4°C to about 17°C, about 4°C to about 16°C, about 4°C to about 15°C, about 4°C to about 14°C, about 4°C to about 13°C, about 4°C to about 12°C, about 4°C to about 11°C, about 4°C to about 10°C, about 4°C to about 9°C, about 4°C to about 8°C, about 4°C to about 7°C, about 4°C to about 6°C, and about 4°C to about 5°C.
[0059] In some embodiments, the sample is maintained at a temperature range selected from the group consisting of about 5°C to about 25°C, about 5°C to about 24°C, about 5°C to about 23°C, about 5°C to about 22°C, about 5°C to about 21°C, about 5°C to about 20°C, about 5°C to about 19°C, about 5°C to about 18°C, about 5°C to about 17°C, about 5°C to about 16°C, about 5°C to about 15°C, about 5°C to about 14°C, about 5°C to about 13°C, about 5°C to about 12°C, about 5°C to about 11°C, about 5°C to about 10°C, about 5°C to about 9°C, about 5°C to about 8°C, about 5°C to about 7°C, and about 5°C to about 6°C.
[0060] In an embodiment of the invention, the diluted sperm sample is maintained at a temperature range of about 6° C. to about 20° C. In some embodiments, the sample is maintained at a temperature range selected from the group consisting of about 6° C. to about 25° C., about 6° C. to about 24° C., about 6° C. to about 23° C., about 6° C. to about 22° C., about 6° C. to about 21° C., about 6° C. to about 20° C., about 6° C. to about 19° C., about 6° C. to about 18° C., about 6° C. to about 17° C., about 6° C. to about 16° C., about 6° C. to about 15° C., about 6° C. to about 14° C., about 6° C. to about 13° C., about 6° C. to about 12° C., about 6° C. to about 11° C., about 6° C. to about 10° C., about 6° C. to about 9° C., about 6° C. to about 8° C., and about 6° C. to about 7° C.
[0061] In some embodiments, the sample is maintained at a temperature range selected from the group consisting of about 7°C to about 25°C, about 7°C to about 24°C, about 7°C to about 23°C, about 7°C to about 22°C, about 7°C to about 21°C, about 7°C to about 20°C, about 7°C to about 19°C, about 7°C to about 18°C, about 7°C to about 17°C, about 7°C to about 16°C, about 7°C to about 15°C, about 7°C to about 14°C, about 7°C to about 13°C, about 7°C to about 12°C, about 7°C to about 11°C, about 7°C to about 10°C, about 7°C to about 9°C, and about 7°C to about 8°C.
[0062] In some embodiments, the sample is maintained at a temperature range selected from the group consisting of about 8°C to about 25°C, about 8°C to about 24°C, about 8°C to about 23°C, about 8°C to about 22°C, about 8°C to about 21°C, about 8°C to about 20°C, about 8°C to about 19°C, about 8°C to about 18°C, about 8°C to about 17°C, about 8°C to about 16°C, about 8°C to about 15°C, about 8°C to about 14°C, about 8°C to about 13°C, about 8°C to about 12°C, about 8°C to about 11°C, about 8°C to about 10°C, and about 8°C to about 9°C.
[0063] In some embodiments, the sample is maintained at a temperature range selected from the group consisting of about 9°C to about 25°C, about 9°C to about 24°C, about 9°C to about 23°C, about 9°C to about 22°C, about 9°C to about 21°C, about 9°C to about 20°C, about 9°C to about 19°C, about 9°C to about 18°C, about 9°C to about 17°C, about 9°C to about 16°C, about 9°C to about 15°C, about 9°C to about 14°C, about 9°C to about 13°C, about 9°C to about 12°C, about 9°C to about 11°C, and about 9°C to about 10°C.
[0064] In some embodiments, the sample is maintained at a temperature range selected from the group consisting of about 10°C to about 25°C, about 10°C to about 24°C, about 10°C to about 23°C, about 10°C to about 22°C, about 10°C to about 21°C, about 10°C to about 20°C, about 10°C to about 19°C, about 10°C to about 18°C, about 10°C to about 17°C, about 10°C to about 16°C, about 10°C to about 15°C, about 10°C to about 14°C, about 10°C to about 13°C, about 10°C to about 12°C, and about 10°C to about 11°C.
[0065] In some embodiments, the sample is maintained at a temperature range selected from the group consisting of about 11°C to about 25°C, about 11°C to about 24°C, about 11°C to about 23°C, about 11°C to about 22°C, about 11°C to about 21°C, about 11°C to about 20°C, about 11°C to about 19°C, about 11°C to about 18°C, about 11°C to about 17°C, about 11°C to about 16°C, about 11°C to about 15°C, about 11°C to about 14°C, about 11°C to about 13°C, and about 11°C to about 12°C. In some embodiments, the sample is maintained at a temperature range selected from the group consisting of about 12°C to about 25°C, about 12°C to about 24°C, about 12°C to about 23°C, about 12°C to about 22°C, about 12°C to about 21°C, about 12°C to about 20°C, about 12°C to about 19°C, about 12°C to about 18°C, about 12°C to about 17°C, about 12°C to about 16°C, about 12°C to about 15°C, about 12°C to about 14°C, and about 12°C to about 13°C. In some embodiments, the sample is maintained at a temperature range selected from the group consisting of about 13°C to about 25°C, about 13°C to about 24°C, about 13°C to about 23°C, about 13°C to about 22°C, about 13°C to about 21°C, about 13°C to about 20°C, about 13°C to about 19°C, about 13°C to about 18°C, about 13°C to about 17°C, about 13°C to about 16°C, about 13°C to about 15°C, and about 13°C to about 14°C. In some embodiments, the sample is maintained at a temperature range selected from the group consisting of about 14° C. to about 25° C., about 14° C. to about 24° C., about 14° C. to about 23° C., about 14° C. to about 22° C., about 14° C. to about 21° C., about 14° C. to about 20° C., about 14° C. to about 19° C., about 14° C. to about 18° C., about 14° C. to about 17° C., about 14° C. to about 16° C., and about 14° C. to about 15° C. In some embodiments, the sample is maintained at a temperature range selected from the group consisting of about 15° C. to about 25° C., about 15° C. to about 24° C., about 15° C. to about 23° C., about 15° C. to about 22° C., about 15° C. to about 21° C., about 15° C. to about 20° C., about 15° C. to about 19° C., about 15° C. to about 18° C., about 15° C. to about 17° C., and about 15° C. to about 16° C. In some embodiments, the sample is maintained at a temperature range selected from the group consisting of about 16°C to about 25°C, about 16°C to about 24°C, about 16°C to about 23°C, about 16°C to about 22°C, about 16°C to about 21°C, about 16°C to about 20°C, about 16°C to about 19°C, about 16°C to about 18°C, and about 16°C to about 17°C.In some embodiments, the sample is maintained at a temperature range selected from the group consisting of about 17° C. to about 25° C., about 17° C. to about 24° C., about 17° C. to about 23° C., about 17° C. to about 22° C., about 17° C. to about 21° C., about 17° C. to about 20° C., about 17° C. to about 19° C., and about 17° C. to about 18° C. In some embodiments, the sample is maintained at a temperature range selected from the group consisting of about 18° C. to about 25° C., about 18° C. to about 24° C., about 18° C. to about 23° C., about 18° C. to about 22° C., about 18° C. to about 21° C., about 18° C. to about 20° C., and about 18° C. to about 19° C. In some embodiments, the sample is maintained at a temperature range selected from the group consisting of about 19°C to about 25°C, about 19°C to about 24°C, about 19°C to about 23°C, about 19°C to about 22°C, about 19°C to about 21°C, and about 19°C to about 20°C. In some embodiments, the sample is maintained at a temperature range selected from the group consisting of about 20°C to about 25°C, about 20°C to about 24°C, about 20°C to about 23°C, about 20°C to about 22°C, and about 20°C to about 21°C. In some embodiments, the sample is maintained at a temperature range selected from the group consisting of about 21°C to about 25°C, about 21°C to about 24°C, about 21°C to about 23°C, and about 21°C to about 22°C. In some embodiments, the sample is maintained at a temperature range selected from the group consisting of about 22°C to about 25°C, about 22°C to about 24°C, and about 22°C to about 23°C. In some embodiments, the sample is maintained at a temperature range selected from the group consisting of about 23° C. to about 25° C. and about 23° C. to about 24° C. In some embodiments, the sample is maintained at a temperature in the range of about 24° C. to about 25° C.
[0066] In some embodiments, the sample is maintained at a temperature selected from the group consisting of about 1°C, about 2°C, about 3°C, about 4°C, about 5°C, about 6°C, about 7°C, about 8°C, about 9°C, about 10°C, about 11°C, about 12°C, about 13°C, about 14°C, about 15°C, about 16°C, about 17°C, about 18°C, about 19°C, about 20°C, about 21°C, about 22°C, about 23°C, about 24°C, and about 25°C.
[0067] In some embodiments, the time for storing the diluted sperm sample is about 2 hours to 96 hours. In some embodiments, the time for storing the diluted sperm sample is at least 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, 36 hours, 48 hours, 60 hours, 72 hours, 84 hours, or 96 hours. In some embodiments, the time for storing the diluted sperm sample is more than 2 hours. In some embodiments, the time for storing the diluted sperm sample is at least 12 hours. In some embodiments, the time for storing the diluted sperm sample is at least 18 hours. In some embodiments, the time for storing the diluted sperm sample is at least 24 hours. In some embodiments, the time for storing the diluted sperm sample is at least 36 hours. In some embodiments, the time for storing the diluted sperm sample is at least 48 hours. In some embodiments, the time for storing the diluted sperm sample is at least 60 hours.
[0068] In some embodiments, the method includes adding a buffer to the sperm sample to maintain the pH of the sample, hi some embodiments, such a buffer is selected from the group consisting of 2-(N-morpholino)ethanesulfonic acid (MES), (3-(N-morpholino)propanesulfonic acid) (MOPS), piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES), acetate, borate, citrate, glycine, bicarbonate, TRIS, phosphate, HEPES, citric acid, and combinations thereof.
[0069] In embodiments, the present invention provides a method of preserving a sperm sample, comprising diluting a sperm sample with a semen diluent in a ratio of about 10:1 to 1:10, and storing the diluted sample in a sealed insulated container at about 4° C. to about 25° C. for 2 hours, 4 hours, 8 hours, 12 hours, 18 hours, 24 hours, 36 hours, 48 hours, 60 hours, 72 hours, 84 hours, or 96 hours.
[0070] The present invention also provides a method for determining the fertility status of a male individual, the Cap-Score TM Collection kits are provided for use in the methods of the invention, such as for use in an assay. In some embodiments, the collection kits include one or more of the following: one or more sterile sperm storage containers, a transfer pipette, a semen diluent solution, an insulated pouch for storing said storage containers, a cold pack (e.g., KOOLIT® refrigerant) for controlling temperature between about 8° C. and about 20° C., an insulated container for storing the sample / insulation pouch and the cold pack, and instructions for use. In some embodiments, the kits further include a buffer solution for mixing with the sperm sample. In some embodiments, such buffers are selected from the group consisting of MES, MOPS, PIPES, acetate, borate, citrate, glycine, bicarbonate, TRIS, sodium phosphate, HEPES, citric acid, and combinations thereof.
[0071] In some embodiments, the method includes transferring a portion or all of the sperm sample into a 15 mL conical tube using a transfer pipette and collecting the sperm sample in a collection cup; diluting the sperm sample 1:1 (v / v) with semen diluent; packaging the conical tube and its contents in an insulated bubble foil pouch; placing the sample tube packaged in the foil pouch into a Styrofoam box; placing a cold pack cooled to 4° C. on top of the sample tube pack packaged in the bubble foil pouch; sealing the Styrofoam box; and placing the Styrofoam box into a shipping container (see FIG. 2).
[0072] In some embodiments, the method includes diluting a sperm sample in a 15 mL conical tube 1:1 (v / v) with pre-warmed refrigerated medium-TYB medium (TYB diluent; Irvine Scientific; 90129-20 x 5 mL), placing the tube in a foil bubble pouch mailer (Therapak; 56362G), placing a cold pack (Therapak; 562200) maintained at 4°C on the mailer, and storing the mailer / cold pack in a polystyrene foam cooler (6" with 3 / 4" wall thickness). 3 / 8 "x4 7 / 8 "x2 1 / 4 "The process involves placing the cooler in a cardboard box (Figure 2).
[0073] In some embodiments, the method includes transferring a portion or all of the sperm sample into a 15 mL conical tube using a transfer pipette and collecting the sperm sample in a collection cup; diluting the sperm sample 1:1 (v / v) with semen diluent; packaging the conical tube and its contents in an insulated bubble foil pouch; placing the sample tube packaged in the foil pouch into a Styrofoam box; placing a cold pack cooled to -20°C on top of the sample tube pack packaged in the bubble foil pouch; sealing the Styrofoam box; and placing the Styrofoam box into a shipping container.
[0074] In some embodiments, the collected sperm sample is subjected to Cap-Score after addition of semen diluent. TM In some embodiments, the collected sperm sample is subjected to a Cap-Score assay. TMThe sperm samples are processed immediately after collection (without adding semen diluent) for assay. In some embodiments, processing of the sperm sample includes one or more steps selected from the group consisting of removing the semen diluent, washing the sperm sample, resuspending one or more portions of the sperm sample in medium, and adding a capacitation agent to one or more portions of the sperm sample to induce capacitation. In some embodiments, processing includes adding a capacitation buffer or a non-capacitation buffer to a portion of the collected sperm sample (Figure 1).
[0075] In some embodiments, the diluent and seminal plasma are separated from the sperm by centrifugation and subsequent washing of the pelleted sperm sample with medium, for example, washing with mHTF (Irvine Scientific; Reference 90126). In some embodiments, the centrifugation speed ranges from about 50 g to about 20,000 g. In some embodiments, the centrifugation speed ranges from about 100 g to about 2000 g. In some embodiments, the centrifugation speed ranges from about 300 g to about 600 g.
[0076] In some embodiments, ejaculates collected at home in sealed specimen containers (Fisher Scientific, 14-375-462) are liquified at 37° C. in an air incubator. To remove diluent and / or seminal plasma, 1 mL of sample is layered onto 1 mL of Enhance S-Plus Cell Isolation Media (Vitrolife, Reference: 15232 ESP-100-90%). In embodiments, samples are centrifuged at 300 g for 10 min, cell pellets are collected, resuspended in approximately 4 mL of Modified Human Tubal Fluid medium (mHTF) (Irvine Scientific; Reference 90126) and pelleted at 600 g for 10 min.
[0077] In some embodiments, semen diluent is separated by centrifugation of sperm with Enhance S-Plus Cell Isolation Media (Vitrolife; Goteborg, Sweden; Catalog No. 15232 ESP-100-90%) and sperm are washed with medium, e.g., modified Human Tubal Fluid Medium (mHTF; Irvine Scientific, Santa Ana, CA; Catalog No. 90126). Sperm sample tubes are centrifuged at 600 g for 10 minutes. In some embodiments, sperm cells are resuspended in medium containing a sperm capacitation agent (e.g., 2-hydroxypropyl-β-cyclodextrin (Sigma; St. Louis, MO; Catalog No. C0926) such as mHTF (Cap) and optionally medium without sperm capacitation agent such as mHTF (NonCap) (FIG. 1).
[0078] In some embodiments, sperm cells were separated from the semen diluent by centrifugation at 300g for 10 minutes in Ehance S-Plus Cell Isolation Media (Vitrolife, Englewood, CO, Reference: 15232 ESP-100-90%). In one embodiment, sperm cells were collected and resuspended in about 4mL of human tubal fluid (HTF) (Irvine Scientific, Santa Ana, CA, Reference 90125) or modified human tubal fluid (mHTF) (Irvine Scientific, Reference 90126) and centrifuged again at 600g for 10 minutes. The resulting sperm cell pellet was resuspended in HTF or mHTF and divided into two separate aliquots incubated with capacitation agent (Cap) and, optionally, without capacitation agent (Non-Cap). The sperm concentration was adjusted to 10 million sperm cells / ml per tube and incubated at 37°C for 3 hours. In some embodiments, sperm cells are incubated in HTF containing bicarbonate buffer in an incubator with 5% CO at 37° C. In some embodiments, sperm cells are incubated in mHTF containing HEPES buffer in an air incubator at 37° C.
[0079] In some embodiments, after incubation with or, optionally, without a capacitation agent, the sperm sample is evaluated using a Cap-Score TM In another embodiment of the invention, incubation with a capacitation agent is performed after transportation and / or storage for at least 18 hours.
[0080] In some embodiments, the isolated sperm cells are subjected to one or more selection processes selected from the group consisting of: forming a layer on top of them and centrifuging through a density gradient; forming a layer on top of them and centrifuging through a density gradient, then recovering a sperm-rich fraction followed by resuspension and washing; forming a layer on top of them and centrifuging through a density gradient, then recovering a sperm-rich fraction, then layering on top of them with a less dense medium into which the motile sperm swim up; layering a less dense medium on top of the sample and allowing the motile sperm to swim up into it.
[0081] In some embodiments, sperm cells are counted and a predetermined number of sperm are placed in a container (e.g., a tube) and diluted with non-capacitation medium or capacitation agent-containing medium to achieve a desired final concentration of sperm. In some embodiments, the desired final concentration of sperm is 10 million / mL (final concentration range is 250×10 3 Sperm / mL ~ 250 x 10 6 (can vary in the range of sperm / mL).
[0082] In some embodiments, media useful in the present invention (e.g., media for resuspending sperm, media for washing sperm samples, and / or media for incubating sperm under non-capacitation and capacitation conditions) are physiological buffer solutions. In some embodiments, the media are selected from the group consisting of human tubal fluid (HTF); modified human tubal fluid (mHTF); Whitten's medium; modified Whitten's medium; KSOM; phosphate-buffered saline; HEPES-buffered saline; Tris-buffered saline; Ham's F-10; Tyrode's medium; modified Tyrode's medium; TES-Tris(TEST)-egg yolk buffer; or Biggers, Whitten, and Whittingham (BWW) medium. In some embodiments, the media comprises one or more of the listed or mixed protein sources. In some embodiments, the protein source is selected from the group consisting of fetal umbilical cord serum ultrafiltrate, plasmanate, egg yolk, skim milk, albumin, lipoprotein, and fatty acid binding protein. In some embodiments, the addition of protein to the medium improves survival and / or helps induce capacitation.
[0083] In some embodiments, the sperm sample is Cap-Score TM The cells are contacted with at least one capacitation agent to perform the analysis. In some embodiments, the capacitation stimulus is one or more of bicarbonate (typically 20-25 mM with a range of 5-50 mM), calcium (typically 1-2 mM with a range of 0.1-10 mM), and / or cyclodextrin (typically 1-3 mM with a range of 0.1-20 mM). In some embodiments, the cyclodextrin is selected from the group consisting of 2-hydroxypropyl-β-cyclodextrin, methyl-β-cyclodextrin, and combinations thereof.
[0084] In some embodiments, the capacitation agent or stimulus is selected from the group consisting of bicarbonate ions, calcium ions, mediators of sterol efflux, and combinations thereof. In some embodiments, the mediators of sterol efflux are selected from the group consisting of 2-hydroxypropyl-β-cyclodextrin, methyl-β-cyclodextrin, serum albumin, high density lipoproteins, phospholipid vesicles, fetal umbilical cord serum ultrafiltrate, fatty acid binding proteins, liposomes, and combinations thereof. In some embodiments, capacitation of a control sample or, optionally, exposure to non-capacitation conditions can be performed in parallel with the test sample.
[0085] In some embodiments, the incubation temperature with the capacitation agent or stimulus is about 30°C to about 40°C, about 30°C to about 39°C, about 30°C to about 38°C, about 30°C to about 37°C, about 30°C to about 36°C, about 30°C to about 35°C, about 30°C to about 34°C, about 30°C to about 33°C, about 30°C to about 32°C, or about 30°C to about 31°C. In some embodiments, the incubation temperature is about 30°C, about 31°C, about 32°C, about 33°C, about 34°C, about 35°C, about 36°C, about 37°C, about 38°C, about 39°C, or about 40°C. In some embodiments, the incubation time with the capacitation agent is about 30 minutes to about 18 hours. In some embodiments, the incubation time is about 1 hour to about 4 hours. In some embodiments, the incubation time is about 30 minutes, i.e., 0.5 hours. In some embodiments, the incubation time is about 1 hour. In some embodiments, the incubation time is about 2 hours. In some embodiments, the incubation time is about 3 hours. In some embodiments, a baseline sample or measurement is taken at the start of the incubation period.
[0086] In some embodiments, the sperm cells are incubated with or without a capacitation agent in G M1 The pattern is fixed for visualization. Fixation is performed for some G M1Although not necessary to evaluate the pattern, fixation preserves the sperm cells, thus enhancing the opportunity to visualize the sperm cells and making them immobile. A variety of fixatives for the histological study of sperm are within the knowledge of one of skill in the art. In some embodiments, suitable fixatives include paraformaldehyde, glutaraldehyde, Bouin's fixative, and fixatives including sodium cacodylate, calcium chloride, picric acid, tannic acid, and the like. In some embodiments, paraformaldehyde, glutaraldehyde, or combinations thereof are used.
[0087] In some embodiments, the amount of fixative is selected from the group consisting of about 0.004% (wt / vol) paraformaldehyde to about 4% (wt / vol) paraformaldehyde, about 0.01% to about 1% (wt / vol) paraformaldehyde, about 0.005% (wt / vol) paraformaldehyde to about 1% (wt / vol) paraformaldehyde, about 4% paraformaldehyde (wt / vol), about 0.1% glutaraldehyde (wt / vol), and about 5 mM CaCl in phosphate buffered saline.
[0088] In preliminary studies, bicarbonate (HCO3 - ) or HEPES buffered medium, the Cap-Score TM No differences were observed in viability or sperm recovery in the assay. The capacitation stimulus consisted of 2-hydroxypropyl-β-cyclodextrin (Sigma, St. Louis, MO, Catalog No. C0926). In pilot studies, this stimulus was shown to improve the Cap-Score TM A 3-hour incubation was shown to be as effective as 6 hours with albumin in promoting human sperm capacitation as measured by Cap-Score. After incubation, samples were fixed with paraformaldehyde (Electron Microscopy Services, Catalog No. 15712). In some embodiments, the Cap-Score was used to measure the fertilization capacity of human spermatozoa. TM The assay is performed on a sperm sample as described in the present invention. TMThe assay is a proprietary assay developed by Androvia LifeSciences and described in U.S. Patent Application Nos. 15 / 512,357, 15 / 387,965, and 15 / 435,875. TM The assay is M1 Using affinity binding molecules with specific affinity for gangliosides, G-glucose binding sites of live or fixed sperm cells were identified. M1 The difference in distribution patterns is measured. In some embodiments, the affinity molecule is directly linked to a detectable label (e.g., a fluorophore). In some embodiments, the affinity molecule is detected by a second affinity molecule that has a detectable label. In some embodiments, a labeled (e.g., fluorescently labeled) cholera toxin b subunit is used to detect G M1 A distribution pattern is obtained. In some embodiments, the amount of cholera toxin b subunit fluorophore label used is about 0.01 to about 10.0 μg / ml. In some embodiments, the amount of cholera toxin b subunit fluorophore label used is about 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3 , 2.4, 2.4, 2.6, 2.7, 2.7, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 6.0, 7.0, 8.0, 9.0, or 10.0 μg / mL. In some embodiments, the amount is about 2 μg / mL. In some embodiments, a labeled antibody against the cholera toxin b subunit is used to detect G M1 The distribution pattern is visualized. In some embodiments, M1A labeled secondary antibody is used that binds either a primary antibody that binds directly to the β subunit of cholera toxin or a primary antibody that binds to the b subunit of cholera toxin. In some embodiments, other detectable labels useful in the present invention are selected from radionuclides, enzymes, fluorescers, or chromophores. In some embodiments, the detection of G in a sperm sample according to the present invention is carried out in a manner similar to that described above. M1 Labeling (or staining) and visualization of the distribution is performed by standard techniques known in the art, including the use of polyclonal and monoclonal antibodies, G M1 These include, but are not limited to, generating peptidomimetics of the relevant epitope of the molecule, or mimicking binding to a small molecule.
[0089] As fully described in U.S. Patent Application Nos. 15 / 512,357, 15 / 387,965, and 15 / 435,875, Cap-Score TM is the G of capacitated and non-capacitated sperm samples. M1 The distribution patterns were compared and a Cap-Score was calculated based on the differences in those patterns, which reflects the percentage of sperm that respond to the capacitation stimulus. TM For human sperm, several different G M1 Patterns were reported. These patterns are designated as INTER (intermediate), APM (acrosomal plasma membrane), AA (apical acrosome), PAPM (post-acrosomal plasma membrane), AA / PA (apical acrosome / post-acrosome), ES (equatorial segment), DIFF (diffuse), and Lined Cell. The fertility threshold is the value of the level of AA and / or APM at which the increase in fertility of the population for increasing the level of AA and / or APM substantially stops. Individuals can be labeled as "infertile", "quasi-infertile", or "non-infertile" based on the individual's AA and / or APM levels (see Example 1 of US Patent Application Serial No. 15 / 512,357). In an embodiment, the percentage of cells with patterns indicative of capacitation (e.g., AA+APM) was evaluated.
[0090] The present invention also provides a method for determining the fertility status of a male individual, the Cap-Score TM Collection kits are provided for use in the methods described herein, including for use in assays. In some embodiments, the collection kits include one or more of the following: one or more sterile sperm storage containers, a transfer pipette, a semen diluent solution, an insulated pouch for storing said storage containers, a cold pack for controlling temperature between about 4° C. and about 25° C., an insulated container for storing the sample / insulation pouch and the cold pack, and instructions for use. In some embodiments, the kits further include a buffer solution for mixing with the sperm sample. In some embodiments, the buffer is selected from the group consisting of MES, MOPS, PIPES, acetate, borate, citrate, glycine, bicarbonate, TRIS, sodium phosphate, HEPES, citric acid, and combinations thereof.
[0091] In some embodiments, the kit includes instructions for use, labels and containers / bags / pouches useful for shipping, storage, and identification purposes. In some embodiments, the kit includes a foil pouch, a biohazard bag containing absorbent material for mailing the sperm sample, a resealable bag containing absorbent, and a foam tube placeholder. In some embodiments, the container can be glass, plastic, or other durable material.
[0092] In some embodiments, the kit comprises one or more of the following: a capacitation medium, a non-capacitation medium, a fixative composition, a G M1 Reagents for determining staining patterns, comparison charts, predetermined standards, G for comparison M1 A pattern expression, or threshold.
[0093] In some embodiments, the kit further comprises a cell isolation medium (e.g., Enhance S-Plus Cell Isolation Media, 90%, Vitrolife, Reference: 15232 ESP-100-90%).
[0094] In some embodiments, the kit may further comprise a large orifice pipette tip (e.g., 200 μL large orifice tip, USA Scientific, catalog number 1011-8400) or a large orifice transfer pipette (e.g., General Purpose Transfer Pipets, Standard Bulb Reference Number: 202-20S, VWR catalog number 14670-147).
[0095] In some embodiments, the kits can further include collection and / or storage tubes, such as 1.5 mL tubes (e.g., USA Scientific, Catalog No. 14159700) and / or 120 mL specimen collection cups (Fisher Scientific, 14375462). In some embodiments, one or more of the collection tubes contains a cyclodextrin that stimulates capacitation. In some embodiments, a capacitation agent, such as a cyclodextrin, is provided separately in the kit.
[0096] In some embodiments, the kit further comprises density gradient material and / or instructions for removing seminal plasma or semen diluent from the sperm sample. EXAMPLES
[0097] The embodiments encompassed herein will now be described with reference to the following examples, which are provided for illustrative purposes only, and the disclosure encompassed herein should not be construed as being limited in any way to these examples, but rather as encompassing any variations that become evident as a result of the teachings provided herein.
[0098] Materials and Methods for All Examples The following example demonstrates the use of a collection kit whereby the collected sperm sample was maintained for an extended period of time (eg, greater than 2 hours).
[0099] Sperm samples were collected by male donors into 120 mL specimen containers and allowed to liquefy for at least 15 minutes and no more than 2 hours, then transferred to a 15 mL conical tube using a large orifice transfer pipette. Sperm samples were diluted 1:1 with Semen Diluent and placed in an insulated box containing cold packs to maintain the temperature at approximately 4 to approximately 25°C. Maintenance of samples at low temperatures averaged at least 12 hours.
[0100] After overnight maintenance at low temperature, sperm cells were separated from seminal plasma and diluent. This was accomplished by layering 1 mL of semen / diluent on top of Enhance S-Plus Cell Isolation Media (1 mL) in a 15 mL conical tube. A sufficient number of conical tubes were used to separate the sperm from the entire volume of semen / diluent. The tubes containing semen / diluent and cell isolation media were centrifuged at 300 g for 10 minutes. The seminal plasma and diluent were removed from all tubes and the bottom ~1 mL fraction was transferred to a new 15 mL tube and then resuspended in 4 mL of mHTF. The resuspended sperm were centrifuged at 600 g for 10 minutes. The supernatant was removed and the sperm cell pellet was resuspended in ~0.25 mL of mHTF. The washed sperm cells were then assessed for concentration and motility. The sperm cells were then split into two tubes, each with a final volume of 300 μL and a final sperm concentration of 10,000,000 cells / mL. The first tube contained 300 μL of mHTF (non-capacitation conditions) and the second tube contained 300 μL of mHTF and a final concentration of 3 mM 2-hydroxypropyl-β-cyclodextrin (capacitation conditions). The sperm cells were incubated at 37° C. for 3 hours.
[0101] After the incubation period, the contents of each tube were gently mixed and 33 μL of 1% (w / v) paraformaldehyde was added to achieve a final concentration of 0.1%. In some embodiments, 0.1% (w / v) paraformaldehyde was added to achieve a final concentration of 0.01%. The tubes were gently mixed and kept at room temperature overnight. The next day, 1 μL of 0.5 mg / mL cholera toxin b subunit conjugated to Alexa Fluor 488 was added. The contents of the two tubes were gently mixed again and left at room temperature for an additional 10 minutes. 5 μL was removed from each tube and placed on a glass slide for evaluation by fluorescence microscopy.
[0102] After transport, processing, incubation, and overnight fixation, each sample was labeled with 2 μg / mL Alexa Fluor 488-conjugated cholera toxin beta subunit (Thermo Fisher Scientific, Waltham, MA, Cat. No. C34775). After 10 min, 5 μL of labeled sperm was placed on a microscope slide, covered with a coverslip (22 × 22 mm no. 1), and transferred to the imaging station.
[0103] Imaging was performed on a Nikon Eclipse NI-E microscope equipped with CFI60 Plan Apochromat Lambda 20× Objectives, C-FL AT GFP / FITC Long-Pass Filter Sets, Hamamatsu ORCA-Flash 4.0 cameras, H101F-ProScan III Open Frame Upright Motorized H101F Flat Top Microscope Stages, and 64-bit imaging workstations running NIS Elements software (Nikon; Melville NY).
[0104] The percentage of sperm in samples that underwent capacitation was determined and reported as Cap-Score (number of sperm with capacitation-associated patterns / (number of sperm with capacitation-associated patterns + number of sperm with other patterns)). All readings were performed according to proven methods (Moody, Cardona et al. 2017) and in accordance with Clinical Laboratory Improvement Amendments (CLIA)-College of American Pathologists (CAP)- and Clinical Laboratory Evaluation Program (CLEP)-approved quality control and assurance best practices. Briefly, if sufficient sperm were present in the sample, at least 150 total patterns were determined for each condition. If insufficient cells were available, the Cap-Score was calculated. TM A minimum of 100 patterns was required to calculate , otherwise the sample was rejected.
[0105] Example 1. Effect of semen diluent and temperature on sperm cell viability during 24 hour storage / transport Semen samples were collected and divided according to the usual procedure. Half was used as control and the other half was used as test. Control samples were processed to create two treatment groups, one with capacitation stimulation (Control-CAP) and the other without capacitation stimulation (Control-NonCAP). Samples were incubated, fixed and kept overnight before being evaluated for Cap-Score (Control-CAP-24hr-fixed and Control-NonCAP-24hr-fixed). Test samples were diluted 1:1 in refrigerated medium (TYB diluent) and kept overnight with cold packs in one experiment (Test-CP) and in the other experiment in the refrigerator (Test-Ref). After keeping overnight in TYB diluent at low temperature, test samples were processed to create treatment groups containing capacitation stimulation (Test-"CP or Ref"-CAP). The samples were incubated, fixed and again kept overnight before the Cap-Score was determined (Test-"CP or Ref"-CAP-24h-Fixation) (Figure 1).
[0106] Semen samples 1 to 8 in Table 1 below were collected by masturbation and allowed to liquefy for up to 2 hours (Moody, Cardona et al. 2017). After liquefaction, the samples were divided (Figure 1). Half were used as a control and the other half was scored using the Cap-Score. TMThe remaining half was used as the control and processed normally. The other half was used as the test treatment and was diluted 1:1 in prewarmed refrigerated medium (TYB diluent; Irvine Scientific; 90129-20X5mL [176 mM 2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]ethanesulfonic acid [TES], 80 mM 2-amino-2-(hydroxymethyl)propane-1,3-diol [Tris], 9 mM dextrose, 10 μL gentamicin sulfate, 20% v / v heat-inactivated egg yolk]). Two different overnight maintenance protocols were evaluated for the test samples to simulate the time and potential environment experienced during transport of the samples from the patient's home to the laboratory for processing. First, some test samples were maintained in a styrofoam box with cold packs cooled to 4°C (Test-CP; Figure 2; n=5). The 15 mL conical tube containing the sample and diluent was placed in an insulating foil pouch (Figure 2A). The cold pack was wrapped in the pouch at 4 °C and secured with a rubber band (Figure 2B). The sample, pouch, and cold pack were placed in a styrofoam box (Figure 2C). The sample, pouch, cold pack, and styrofoam box were then placed in a cardboard box and maintained overnight (Figure 2D). A temperature probe was inserted into the pouch to read the temperature every 5 minutes (Figure 2E). A representative temperature profile is shown in Figure 3. Some test samples were then maintained in a refrigerator at 4 °C (Test-Ref; Figure 4; n = 3). Approximately 20 mL of water was added to the 50 mL tube (Figure 4A). The 15 mL conical tube containing the diluted sample was placed in the water (Figure 4B). The conical tube was placed in a collection cup and placed in a refrigerator maintained at 4 °C (Figure 4C). A temperature probe was inserted into a water bath to read the temperature every 5 minutes (Figure 4D). A typical temperature profile is shown in Figure 5.
[0107] After liquefaction of the controls and overnight maintenance of the test samples, sperm were removed from the seminal plasma or TYB diluent by centrifugation through Enhance S-Plus Cell Isolation Media (Vitrolife; Goteborg, Sweden; catalog no. 15232 ESP-100-90%) and cultured in modified Human Tubal Fluid medium (mHTF; Irvine Scientific, Santa Ana, CA; catalog no. 90126, 97.8 mM NaCl, 4.69 mM KCl, 0.20 mM MgSO4, 0.37 mM KH2PO4, 2.04 mM CaCl2, 4 mM NaHCO3, 21 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid [HEPES], 2.78 mM CH6H2O4, 0.2 mM EDTA ... 12 O6, 0.33 mM sodium pyruvate, 21.4 mM sodium lactate, 10 μg / ml gentamicin, 5 mg / L phenol red). To facilitate capacitation, sperm were resuspended in mHTF without (NonCAP) or with (CAP) 2-hydroxypropyl-β-cyclodextrin (Sigma; St. Louis, MO; catalog no. C0926) (Moody, Cardona et al. 2017). After 3 h of incubation, samples were fixed. For control samples, Cap-Scores for NonCAP and CAP were determined approximately 24 h after fixation (Control-CAP-24h-fixed and Control-NonCAP-24h-fixed). For test samples, Cap-Scores were determined after an additional overnight stay at room temperature (Test-CP-CAP-24h-fixed or Test-Ref-CAP-24h-fixed). Because exposure of sperm to TYB can limit capacitation (Ostermeier, Cardona et al. 2018), it is anticipated that samples will require an additional overnight fixation to reach maximal capacitation levels.
[0108] Semen samples were collected and divided as shown in Figure 6. Half was used as control and half was used as test. Control samples were liquidized and then samples without capacitation stimulation (Control-NonCAP) and with capacitation stimulation (Control-CAP) were made. After incubation, control samples were fixed and kept overnight and then evaluated for Cap-Score (Control-NonCAP-24hr-fixed and Control-CAP-24hr-fixed). In this series of experiments, test samples were first diluted in refrigerated medium and then kept overnight with cold packs (Test-CP). These samples were then processed, incubated, fixed overnight and Cap-Score was determined (Test-CP-CAP-24hr-fixed). As ejaculates (n=5) were divided, paired t-tests were used for pre-planned comparisons. As expected, Control-CAP-24hr-fixation was greater than Control-NonCAP-24hr-fixation (p<0.001).No difference was found between Control-CAP-24hr-fixation and Test-CP-CAP-24hr-fixation (p=0.865).
[0109] Semen samples were collected and divided as shown in Figure 7. Half was used as control and half was used as test. Control samples were liquidized and then samples without capacitation stimulation (Control-NonCAP) and with capacitation stimulation (Control-CAP) were made. After incubation, control samples were fixed and kept overnight before being evaluated for Cap-Score (Control-NonCAP-24h-fixed and Control-CAP-24h-fixed). Test samples were first diluted in refrigerated medium and then kept overnight in the refrigerator (Test-Ref). These samples were then processed, incubated, fixed overnight, and the Cap-Score was determined (Test-Ref-CAP-24h-fixed). As ejaculates (n=3) were divided, paired t-tests were used for preplanned comparisons. As expected, Control-CAP-24h-fixed was greater than Control-NonCAP-24h-fixed (p<0.021). No difference was found between Control-CAP-24h-fixation and Test-Ref-CAP-24h-fixation (p=0.482).
[0110] The Cap-Score was greater (p<0.05) for the Control-CAP-24hr-fixed samples when compared to the Control-NonCAP-24hr-fixed in both the cold pack experiment (Figure 6) and the refrigerator experiment (Figure 7). This indicates a good capacitation response in both experiments using the standard approach. Similar Cap-Score values were observed between Control-CAP-24hr-fixed and Test-CP-CAP-24hr-fixed (Figure 6), indicating that ejaculates can be kept overnight in TYB diluent and processed the next day. Similarly, in the refrigerator experiment, the Cap-Score of Control-CAP-24hr-fixed was not different from the Test-Ref-CAP-24hr-fixed samples (Figure 7). This observation further indicates that ejaculates can be kept overnight in refrigerated medium and processed for Cap-Score the next day.
[0111] The temperature profiles generated in the cold pack experiment cooled to 4°C (Figure 3) and the 4°C refrigerator experiment (Figure 5) appear to be different from each other. In the cold pack setup, the temperature dropped to about 11°C in about 0.75 hours and then returned to room temperature (about 20°C) in about 4.5 hours. Thus, the samples were maintained at room temperature for about 19 hours. In contrast, in the refrigerator setup, the temperature dropped to about 4°C in about 2.5 hours and remained at that temperature until the samples were processed the next day. These results suggested that sperm in TYB diluent could be maintained overnight at a wide temperature range and then processed to obtain Cap-Scores comparable to those generated using standard processing.
[0112] To determine if a more gradual temperature profile could be generated and if the sample could be prevented from reaching any of the extreme environments mentioned above, a mock sample was placed in a box with an ice pack cooled to -20°C (Figure 8). A 15 mL conical tube containing the sample and diluent was placed in an insulated foil pouch (Figure 8A). The foil pouch was wrapped around the sample and secured with a rubber band before being placed in a Styrofoam box (Figure 8B). An ice pack equilibrated to -20°C was placed on top of the secured pouch and sample (Figure 8C). The sample, pouch, ice pack, and Styrofoam box were placed in a cardboard box and maintained overnight (Figure 8D). A temperature probe was inserted into the pouch to take temperature readings every 5 minutes (Figure 8E). A representative profile is shown in Figure 9. Indeed, using the ice pack setup, the sample reached approximately 12°C in about 1 hour and did not return to room temperature until approximately 19.5 hours had passed.
[0113] Taken together, these data show that the Cap-Score at home TM It supports the development of collection kits that would allow patients to conveniently collect ejaculate at home and send it overnight to a centralized laboratory for processing.
[0114] Cap-Score TMThe assay was performed on diluted human sperm samples that had been subjected to various temperature treatments during storage to determine the effect of diluent solutions and temperature control on the sperm cells' ability to capacitate. Cap-Score TM The results of the assay are summarized in Table 1. Table 1. Effect of diluent and temperature on sperm capacitation scores [Table 1] 1 Test-CP-CAP-24hr-Fixation Time = 24hr; Sperm samples were diluted in TYB and stored in a Styrofoam box cooled with cold packs at 4°C. 2 Test-Ref-CAP-24hr-Fixed: Time = 24hr; sperm samples were diluted in TYB and stored in the refrigerator at 4°C.
[0115] Control samples were liquified and then processed to generate samples without capacitation stimuli (Control-NonCAP) and with capacitation stimuli (Control-CAP) for diluted semen samples kept overnight with cold packs (Test-CP). After incubation, control samples were fixed and kept overnight and then evaluated for Cap-Score (Control-NonCAP-24h-fixed and Control-CAP-24h-fixed). In this series of experiments, test samples were first diluted in refrigerated medium and then kept overnight with cold packs (Test-CP). These samples were then processed, incubated, fixed overnight, and Cap-Score was determined (Test-CP-CAP-24h-fixed). As ejaculates (n=5) were split, paired t-tests were used for preplanned comparisons. As expected, Control-CAP-24h-fixed was greater than Control-NonCAP-24h-fixed (p<0.001). No difference was found between Control-CAP-24h-fixation and Test-CP-CAP-24h-fixation (p=0.865) (Figure 6).
[0116] For the refrigerator-stored semen samples, the control samples were liquefied and then processed to generate samples without capacitation stimuli (Control-NonCAP) and samples with capacitation stimuli (Control-CAP). After incubation, the control samples were fixed and kept overnight and then Cap-Scored. TM The test samples were first diluted in refrigerated medium and then kept overnight in the refrigerator (Test-Ref). These samples were then treated, incubated, fixed overnight, and evaluated for Cap-Score. TM was determined (Test-Ref-CAP-24h-fixed). Because ejaculates (n=3) were split, paired t-tests were used for preplanned comparisons. As expected, Control-CAP-24h-fixed was greater than Control-NonCAP-24h-fixed (p<0.021). No difference was found between Control-CAP-24h-fixed and Test-Ref-CP-CAP-24h-fixed (p=0.482) (Figure 7).
[0117] The results in Table 1 indicate that there is no significant difference between the control samples and the samples kept at low temperature overnight. The resistance of sperm cells to capacitation over an extended period of time at chilled temperatures to TYB diluent (Irvine Scientific, Cat. No. 90129) resulted in a clinical Cap-Score of 1. TM The need for sperm samples to be collected in a testing laboratory under the supervision of a medical practitioner has been reduced. In other words, the tolerance of sperm cells' ability to capacitate to diluents at temperatures between 8°C and 25°C allows patients to collect sperm samples at home and perform clinical Cap-Score overnight on the diluted sperm sample. TM The convenience of at-home collection of sperm samples that can be sent to a testing laboratory greatly enhances the utility of the Cap-Score assay without compromising accuracy and efficiency.
[0118] Example 2. Cap-Score TM The effect of TEST egg yolk buffer (TYB) and cooling on human spermatozoa capacitation ability as determined by This study was to evaluate the effect of TEST (TES and Tris) egg yolk buffer and cooling on the ability to extend the time to sperm capacitation.
[0119] Semen samples 1 to 3 in Table 2 below were collected and, in liquid form, were divided into control and test samples according to the procedure described in Example 1 above (Figure 1, Moody, Cardona et al. 2017). Half was used as a control, and the other half was used for the Cap-Score test. TM Half of the semen was treated as normal for control and the other half was used as test. Test samples were diluted in TYB medium (Irvine Scientific; 90129-20X 5mL [176 mM 2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]ethanesulfonic acid [TES], 80 mM 2-amino-2-(hydroxymethyl)propane-1,3-diol [Tris], 9 mM dextrose, 10 μL gentamicin sulfate, 20% v / v heat-inactivated egg yolk]). Diluted semen test samples were diluted in a volume ratio of 1:1 (n=5), 1:6 (n=7), or 8:5 (n=5) semen:TYB. TYB dilution test semen samples 1-3 were stored overnight (i.e., approximately 18 h to approximately 24 h) in a sealed insulated Styrofoam box with a cold pack cooled to -20 °C.
[0120] First, after overnight storage, the cooled samples were warmed to room temperature. The samples were then washed and exposed to non-capacitation (NC) or capacitation (CAP) conditions for 3 hours, then fixed overnight and the Cap-Score was determined. The Cap-Scores of test samples 1 to 3 in Table 2 were determined according to the assay procedure described in Example 1 above, and the test samples were compared to the control using a paired t-test.
[0121] In all experiments, the Cap-Score was greater in the control-CAP compared to the control-NC (p<0.05). No significant difference was observed between the control-CAP and the test-CAP at any dilution ratio (ratio 1:1: 39.7±4% vs. 40.0±2%; p=0.87; ratio 1:6: 32.0±4% vs. 34.0±3%; p=0.33; ratio 8:5: 36.0±2% vs. 34.2±1%; p=0.5). Cap-Score TM The results of the study are summarized in Table 2 below. Table 2. Effect of TYB and cooling on sperm capacitation scores [Table 2]
[0122] According to the results in Table 2, good capacitation responses were observed in the control in both experiments, suggesting appropriate stimulation by CAP conditions. The semen:TYB volume ratio was selected to mimic typical ejaculate volumes, and a constant amount of diluent could be utilized in an at-home semen collection kit to maintain sperm capacitation ability. The addition of a constant amount of TYB to a variety of different ejaculate volumes limits user input. The similar Cap-Score values between control-CAP and test-CAP indicate that ejaculates can be maintained overnight in various concentrations of TYB with minimal impact on next-day function, regardless of the ratio.
[0123] This study demonstrated that TYB can extend the fertilizing capacity of sperm. TYB can be used as an effective semen diluent in home collection kits, as described herein.
[0124] Overall, analysis of variance (ANOVA) was used to compare the CAP-Score across all experiments (1:1 cold pack, 1:1 refrigerator, 1:6 ice pack, 8:5 ice pack, 1:1 transport incubator, and 1:1 transport freezer). TMand concentration values were compared. No experimental overall effects were observed for the control or test treatment groups. To ensure samples were maintained within the test temperature range, two temperature monitors were provided within the home collection kit to identify samples that reached -5°C (Telatemp-Cold Snap CT -5°C; see 1:1 transport freezer data) and samples that exceeded 20°C for more than 1 hour (Telatemp-Warm Mark 3TM+20°C; see 1:1 cold pack data).
[0125] Home sample collection can ease the burden of sample processing in resource-limited clinics. It can also facilitate uptake of work-up in men for whom in-clinic sample preparation or privacy in bringing samples to a clinic is a major barrier. It can also extend the geographic availability of sperm function testing to those who live farther from clinics, reducing the financial burden associated with time and effort away from work. [Prior art documents] [Non-patent literature]
[0126] [Non-Patent Document 1] Babigumira et al., Journal of Assisted Reproduction and Genetics, 2018, 35(1): 99-106 [Non-Patent Document 2] Cardona et al., Molecular Reproduction and Development, 2017, 84(5): 423-435; Schinfeld et al., Molecular Reproduction and Development 2018, 85(8-9): 654-664
Claims
1. 1. A method for determining a human male's fertility status, comprising: a) obtaining a sperm sample from a human male; b) introducing a volume of semen diluent solution into said sperm sample in a dilution volume ratio to obtain a diluted sperm sample; c) maintaining the diluted sperm sample at a temperature range of about 4° C. to about 25° C. for an extended period of time of more than 2 hours; d) performing a Cap-Score assay on the diluted sperm sample of step (c) to determine a Cap-Score; and e) determining the fertility status of said human male.
2. 2. The method of claim 1, wherein the Cap-Score obtained from the Cap-Score assay on the diluted sperm sample is not significantly different from the Cap-Score obtained from a fresh sample obtained from the same individual and treated in the same way.
3. 2. The method of claim 1, wherein the temperature range is from about 4°C to about 20°C.
4. The method of claim 3, wherein the temperature range is from about 8°C to about 10°C.
5. 2. The method of claim 1, wherein the semen diluent solution comprises a buffer selected from the group consisting of bicarbonate buffer, citrate buffer, hydroxymethylaminomethane (TRIS) buffer, TRIS / citrate buffer, TRIS / citrate buffer, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer, HEPES / TRIS buffer, N'-tris(hydroxymethyl)methyl-2-aminoethane (TES) and hydroxymethylaminomethane (TRIS) buffer (TES / TRIS buffer), and combinations thereof.
6. The method of claim 5, wherein the buffer is a TES / TRIS buffer.
7. 2. The method of claim 1, wherein the semen diluent solution comprises a protein selected from the group consisting of albumin, fetal umbilical cord serum ultrafiltrate, plasmanate, egg yolk, skim milk, lipoproteins, fatty acid binding proteins, and combinations thereof.
8. The method of claim 7, wherein the protein is egg yolk.
9. 7. The method of claim 6, wherein the semen diluent solution further comprises an antibiotic.
10. 10. The method of claim 9, wherein the antibiotic is gentamicin.
11. 2. The method of claim 1, wherein the Cap-Score assay comprises the steps of: (i) isolating sperm cells from the sperm sample and the semen diluent solution; (ii) resuspending a first portion of the sperm cells in a buffer system containing a capacitation stimulus (Cap) and resuspending a second portion of the sperm cells in a buffer system not containing a capacitation stimulus (non-Cap); and (iii) incubating the resulting cell suspension in the capacitation buffer system and the non-capacitation buffer system at 37° C. for 3 hours.
12. 2. The method of claim 1, wherein the dilution volume ratio of said sperm sample to said semen diluent solution is from about 10:1 to about 1:
10.
13. 2. The method of claim 1, wherein the dilution volume ratio of the sperm sample to the semen diluent solution is about 1:
1.
14. 10. The method of claim 1, wherein the sperm sample is stored in a plastic tube with a conical bottom and a sealing cap.
15. 2. The method of claim 1, wherein the plastic tube is selected from the group consisting of polypropylene, polystyrene, polyethylene terephthalate (PET), low density polyethylene (LDPE), polyallomer (PA), and polycarbonate (PC).
16. 2. The method of claim 1, wherein the extended period is greater than 2 hours and up to about 24 hours.
17. 2. The method of claim 1, wherein the extended period is at least 18 hours.
18. 10. The method of claim 1, further comprising using a sperm sample collection kit comprising one or more of a sperm storage container, a transfer pipette, an insulating pouch, a cold pack, an insulated container, and a semen diluent solution.
19. 1. A method for determining the fertility status of a human male individual, comprising: a) obtaining a sperm sample from a human male; b) introducing a volume of semen diluent solution into said sperm sample in a dilution volume ratio to obtain a diluted sperm sample; c) cooling the diluted sperm sample of step (b) in an insulated container to a temperature ranging from about 8° C. to about 10° C. to obtain a chilled diluted sperm sample; d) maintaining the chilled diluted sperm sample at a temperature range of about 8°C to about 25°C for an extended period of time, said temperature being maintained by placing the diluted sperm sample in an insulated pouch with a cold pack chilled to a predetermined temperature; e) Ganglioside G, which is involved in capacitation M1 and performing a Cap-Score assay on the diluted sperm sample of step (d) to determine a pattern distribution and determine the fertility status of the human male.
20. 20. The method of claim 19, wherein the cooling step (c) is carried out for about 1 hour.
21. 20. The method of claim 19, wherein the extended period of time in step (d) is at least 18 hours.
22. 21. The method of claim 20, wherein the cold pack is cooled to 4°C.
23. 21. The method of claim 20, wherein the cold pack is cooled to -20°C.
24. 20. The method of claim 19, further comprising using a sperm sample collection kit comprising one or more of a sperm storage container, a transfer pipette, an insulating pouch, a cold pack, an insulated container, and a semen diluent solution.
25. A kit for determining male fertility status, comprising one or more of a sperm storage container, a transfer pipette, an insulating pouch, a cold pack, an insulating over-all container, a semen diluent solution, an agent for stimulating capacitation, a capacitation medium, a non-capacitation medium, a fixative reagent, and a G M1 A kit comprising a reagent for determining the distribution of a pattern.
